On March 21, Commerce Minister Wang Wentao met with David A. Ricks, chair and CEO of Eli Lilly and Company, and discussed with him China-US relations and Lilly’s development in China.

Wang Wentao said that health is an important measure of people’s well-being. He stressed China’s commitment to build a Healthy China that puts people first. He said that as the second largest pharmaceutical market in the world, China will create a broad space for Lilly and other multinational pharmaceutical companies. He hoped that Lilly, with years of operation in China, will continue to invest in China and provide more high-quality pharmaceutical products and services to benefit the Chinese people and contribute to the development of the pharmaceutical industry. He reaffirmed China’s commitment to high-quality development through high-standard opening-up, and fostering a market-oriented, law-based and world-class business environment, and sound service provision for foreign-funded enterprises.

David A. Ricks gave a briefing on Lilly’s global business and underlined its commitment to the Chinese market. He expressed willingness to increase investment in China and reinforce R&D cooperation to provide better products and services for the Chinese market.

(All information published on this website is authentic in Chinese. English is provided for reference only.)